Q2 2025 TELA Bio Inc Earnings Call Transcript
Key Points
- TELA Bio Inc (TELA) achieved a record revenue of over $20 million in Q2 2025, marking the first quarter to surpass this milestone.
- The OviTex reinforced tissue matrix portfolio for hernia repair and abdominal wall reconstruction has scaled significantly, with over 73,000 units sold across the US and Europe.
- The company secured contracts with three major national GPOs for LIQUIFIX, with two contracts recognizing it as an innovative technology.
- European sales grew 25% year-over-year, driven by 29% unit growth, and TELA Bio Inc (TELA) secured a four-year framework agreement with the NHS in England.
- The company reported a gross margin increase to 69.8% in Q2 2025, up from 68.8% in the prior year period, due to lower charges for excess and obsolete inventory.
- TELA Bio Inc (TELA) reported a net loss of $9.9 million in Q2 2025, although this was an improvement from a $12.6 million loss in the prior year period.
- Sales and marketing expenses increased slightly to $16.9 million, primarily due to higher commission expenses, despite a decrease in headcount.
- General and administrative expenses rose to $4.1 million from $3.6 million in the prior year period.
- The company is in a transition phase from focusing on complex hernia procedures to a broader portfolio, which may impact short-term growth.
- Despite strong growth in the OviTex PRS portfolio, the OviTex unit volume growth decelerated, indicating potential challenges in maintaining momentum.
Thank you for standing by, and welcome to TELA Bio's second-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to turn the call over to Louisa Smith from the Gilmartin Group. Please go ahead.
Thank you, [Latif], and good afternoon, everyone. Earlier today, TELA Bio released financial results for the second-quarter 2025. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, Chief Executive Officer; Jeff Blizzard, President; and Roberto Cuca, Chief Operating Officer and Chief Financial Officer.
Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific factors that may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
